Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis
This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).
Actinic Keratosis
DRUG: Vehicle gel|DRUG: SR-T100 with 2.3% of SM
Total clearance rate:, The proportion of patients achieving total clearance of AK lesions in the treatment area (in total of 25cm2 area) at 8-week post-EOT visit (scheduled at Week 24 visit) ., 8-week post-EOT visit (scheduled at Week 24 visit)
Partial clearance rate, The proportion of patients achieving â‰¥ 75% total clinically assessed AK lesion counts out of all target lesions in the treatment area (in total of 25cm2 area) at the post-EOT visit (8 weeks after EOT visit)., 24 week
This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).